Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026)

Emergent BioSolutions' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.6 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, changed N/A from the prior year.
• Current Deferred Revenue was $17.6 million for Q1 2026 at Emergent BioSolutions, up from $5.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $17.6 million in Q1 2026 to a low of $5.0 million in Q4 2025.
• Historically, Current Deferred Revenue has averaged $12.8 million across 3 years, with a median of $15.9 million in 2022.
• Biggest YoY gain for Current Deferred Revenue was 85.9% in 2022; the steepest drop was 85.9% in 2022.
• A 3-year view of Current Deferred Revenue shows it stood at $15.9 million in 2022, then slumped by 68.55% to $5.0 million in 2025, then jumped by 252.0% to $17.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $17.6 million (Q1 2026), $5.0 million (Q4 2025), and $15.9 million (Q1 2022), per Business Quant data.